Evidence map›Paper›PMID 39103694›Full record

ReviewDiscover nano2024

Anticancer activity of quantum size carbon dots: opportunities and challenges.

Tanima Bhattacharya, Subham Preetam, Sohini Mukherjee, Sanjukta Kar, Debanjan Singha Roy, Harshita Singh, Arak Ghose, Tanmoy Das, Gautam Mohapatra

Abstract readReview
In one paragraph

Review in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tanima Bhattacharya *Faculty of Applied Science, Lincoln University College, 47301, Petaling Jaya, Selangor Darul Ehsan, Malaysia. btanima1987@gmail.com.
Subham Preetam *Department of Robotics and Mechatronics Engineering, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, 42988, Republic of Korea.
Sohini MukherjeeDepartment of Environmental Science, University of Calcutta, 35 Ballygunge Circular Road, Kolkata, West Bengal, 700019, India.
Sanjukta KarDietetics and Applied Nutrition, Amity University Kolkata, Kadampukur, India.
Debanjan Singha RoyKIIT School of Biotechnology, KIIT University, Bhubaneswar, India.
Harshita SinghKIIT School of Biotechnology, KIIT University, Bhubaneswar, India.
Arak GhoseKIIT School of Biotechnology, KIIT University, Bhubaneswar, India.
Tanmoy DasFaculty of Engineering, Lincoln University College, 47301, Petaling Jaya, Selangor Darul Ehsan, Malaysia. tanmoy.das82@gmail.com.
Gautam MohapatraCentre for Biotechnology, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research into the anticancer activity of quantum-sized carbon dots (CDs) has emerged as a promising avenue in cancer research. This CDs delves into the opportunities and challenges associated with harnessing the potential of these nanostructures for combating cancer. Quantum-sized carbon dots, owing to their unique physicochemical properties, exhibit distinct advantages as potential therapeutic agents. Opportunities lie in their tunable size, surface functionalization capabilities, and biocompatibility, enabling targeted drug delivery and imaging in cancer cells. However, we include challenges, a comprehensive understanding of the underlying mechanisms, potential toxicity concerns, and the optimization of synthesis methods for enhanced therapeutic efficacy. A succinct summary of the state of the research in this area is given in this review, emphasizing the exciting possibilities and ongoing challenges in utilizing quantum-sized carbon dots as a novel strategy for cancer treatment.

Indexed as

AnticancerBiocompatibilityCarbon dotQuantum sizeTherapeutic

Identifiers

PMID39103694
PMCPMC11300426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.